0B68 Schulz, Stephanie - Thomas Jefferson University - Thomas Jefferson University
sxs149

Stephanie Schulz, PhD

Contact Dr. Schulz

1020 Locust Street
JAH 411
Philadelphia, PA 19107

(215) 955-5693
(215) 955-7006 fax

Most Recent Peer-reviewed Publications

  1. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer
  2. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer
  3. GUCY2C molecular staging personalizes colorectal cancer patient management
  4. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C
  5. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes
  6. Molecular staging individualizing cancer management
  7. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity
  8. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice
  9. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer
  10. Contrast-enhanced ultrasound imaging of sentinel lymph nodes after peritumoral administration of sonazoid in a melanoma tumor animal model
  11. Molecular staging estimates occult tumor burden in colorectal cancer
  12. Selection of optimal reference genes for normalization in quantitative RT-PCR
  13. The Hormone Receptor GUCY2C Suppresses Intestinal Tumor Formation by Inhibiting AKT Signaling
  14. Can colorectal cancer be prevented or treated by oral hormone replacement therapy?
  15. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients
  16. Guanylyl cyclase C in colorectal cancer: Susceptibility gene and potential therapeutic target
  17. Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis
  18. Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer
  19. Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms
  20. GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?
0